HTGF has backed a series A round for Cardior Pharmaceuticals, a heart failure-focused spinout of Hannover Medical School.

Cardior Pharmaceuticals, a Germany-based developer of therapies for heart failure, has closed a €15m ($16.5m) series A round co-led by pharmaceutical companies Boehringer Ingelheim and Bristol-Myers Squibb.

Venture capital firm Life Sciences Partners also co-led the round, which included public-private partnership High-Tech Gründerfonds and VC firm BioMedPartners. Boehringer Ingelheim participated through its corporate venturing unit, Boehringer Ingelheim Venture Fund.

Cardior Pharmaceuticals is using RNA technology to predict and treat heart failure, and its lead candidate is an inhibitor of a…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?